Clinical trial · Interventional
The Effect of Education and Telephone Follow-up Given to Cancer Patients Receiving Immunotherapy on Symptom Management and Self-care Power
NCT05683652CI-TRIAL-00063200unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study, it was aimed to evaluate the effects of education and telephone follow-up given to cancer patients receiving immunotherapy on symptom management and self-care power. It is expected that the education given to the patients who will receive immunotherapy for the first time and the monitoring by phone, prevention of immunotherapy-related side effects, early recognition, and follow-up will reduce unnecessary hospital admissions and increase the self-care power of the patient.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Patient | — | UNRESOLVED | — |
| Immunotherapy | — | UNRESOLVED | — |
| Self Care | — | UNRESOLVED | — |
| Symptom Management | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TRAINING BOOKLET | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Nightingale Symptom Rating Scale
- timeFrame
- In patients receiving immunotherapy, the first measurements will be made at the end of the 1st cycle (the cycle is 28 days)
- description
- Nightingale Symptom Assessment Scale (N-SDS) is a quality of life scale developed by Gülbeyaz Can and Adnan Aydıner in 2009 for cancer patients. Consisting of 38 items in total, the scale (N-CSS) has three sub-dimensions: Physical Well-Being (Physician) (items 1-4, 6-15, 23-27 and 37), Social Well-Being (SoIH) (5 and Articles 16-22) and Psychological Well-Being (PSYH) (Articles 28-36 and 38). When each item in the scale is used alone, it can be reflected how the cancer patients who are planned to receive or receiving chemotherapy are affected by the disease/treatment-related problems. In this Likert-type scale, the answer given by the patient to the evaluated item is scored as "0", if it is very little, "1", if it is a little, "2", if it is quite a lot, "3", and if it is too much, it is scored as "4". A high score indicates that the level of being affected by the disease/treatment-related problems is high.
- measure
- Demographic and Medical Characteristics - Patient Information Form
- timeFrame
- It will meet within 3 months with patients who agree to participate in the study.
- description
- It consists of a total of 8 questions created by the researcher after the literature review. 6 questions include medical characteristics, 2 questions include demographic characteristics.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Ability to read and write in Turkish, * Absence of any psychiatric disorder that will reduce the ability to comprehend and understand, * Not having any physical discomfort in the area of hearing or speaking that would prevent telephone conversations, * Will receive immunotherapy for the first time and only, * Willingness to participate in the research, * Willingness to participate in the research, * Patients who agreed to participate in the study verbally and in writing were included in the study. Exclusion Criteria: * Not being voluntarily or willing to participate in the research, * Will receive radiotherapy or chemotherapy together with immunotherapy, * Not knowing that he will receive immunotherapy, * Patients who did not accept to participate in the study were not included in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.